PCI Expands Clinical Distribution with New Facility - Release - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
PCI Expands Clinical Distribution with New Facility - Release

Source: Company News Release

Packaging Coordinators Inc. (PCI) is pleased to announce it has undertaken construction of a new stand-alone Clinical storage and global distribution facility to support its growing business.  PCI plans to break ground this week in anticipation of completing construction in mid-2014. The new state-of-the-art facility will be located in Rockford, Illinois near PCI’s current Clinical packaging, storage, and distribution facility located on the campus of its Rockford commercial pharmaceutical packaging location.  The existing facility was constructed in 2011 to support PCI’s strategic expansion of Clinical services for investigational medicines.  Business growth in the area of global distribution of investigational products has warranted construction of the new purpose-built facility, allowing PCI to provide additional capacity for both storage and global distribution.  The new site complements PCI’s 2012 opening of its European based stand-alone Clinical distribution site in Treforest, Wales located just north of Cardiff in the United Kingdom.

PCI’s new Clinical distribution facility will support ambient and Cold Chain storage of investigational medicines and will be DEA approved for storage of Schedule II-V controlled substances.  The new site is designed to be 93,000 square feet and will be located in the industrial park adjacent to the Chicago Rockford International airport at 5775 Logistics Parkway, located near the intersection of Blackhawk Rd. and Falcon Rd.  PCI is utilizing the services of Cord Construction for the new facility and McClellan Blakemore are the architects of record for the project.  PCI’s proximity to the airport provides convenient international access.  PCI currently distributes Clinical/investigational medicines to investigator sites around the world and industry trends demonstrate continued growth of clinical studies being executed in emerging markets such as South America, Asia, Russia, and Eastern Europe.

“We are very excited about the opportunity to build out our distribution capabilities in support of business growth,” states Bob Misher, Senior Vice President of Global Clinical Services at PCI.  “The ability to package, store, globally distribute, and process returns of investigational medicines all in one state-of-the-art campus is a real benefit to our clients.  This new facility helps us strategically position our business to further support industry trends we are witnessing; the first being international growth in the execution of our clients’ clinical studies, and the second being clients’ investigational medicines needing Cold Chain storage and shipment at 2-8°C, -20°C, and -80°C.  We have been steadily expanding our capabilities in these areas as industry dynamics change.  The location is built to be very accommodating as the industry and the needs of our clients evolve in years to come.”

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here